Human Immunodeficiency Virus InfectionPhase 1NCT05141422
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
A Phase 1 study testing SHR2150 tablet、efavirenz in people with Human Immunodeficiency Virus Infection, run by Jiangsu HengRui Medicine Co., Ltd. at 1 site in China.
Trial summary
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Human Immunodeficiency Virus Infection
- What is being tested?
- SHR2150 tablet、efavirenz
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 13 Dec 2021to 22 Jan 2022
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
- Healthy subjects aged 18 ~ 45 (including the boundary value), male and female;
- Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2 (m2));
- The physical examination, vital signs, laboratory examination, 12-lead electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no clinical significance;
- The subjects with reproduction ability must agree to take effective contraceptive measures after signing the informed consent form and within 7 months (for female) or 4 months (for male) until the last medication.
Who cannot join
- Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results;
- Those who have undergone surgery within 3 months before the trial, or plan to perform surgery during the study period;
- Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval (QTcF) ≥ 450 ms (for male) or > 460 ms (for female) or < 300 ms;
- Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment;
- Have a history of allergies to drugs, food or other substances;
- Those who have used soft drugs or hard drugs; or those with positive results in urine drug abuse screening;
Show all 11Show fewer
- Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration;
- Those who have taken any medicine within 1 month before the first administration (including prescription medicines, non-prescription medicines, Chinese herbal medicines, vitamins, calcium tablets and other food supplements), especially the drugs which have any effect on CYP3A4;
- Regular drinkers within 3 months before the test, that is, drinking more than 15 g of alcohol per day (15 g alcohol = 450 mL of beer, or 50 mL of spirits, or 150 mL of wine), and any alcohol-containing products cannot be stopped during the study;
- Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is positive, or treponema pallidum antibody is positive, or human immunodeficiency virus antibody is positive;
- Women with pregnancy or within lactation period.
Trial locations and contacts
1 site in 1 country.
China1 site
The People's Hospital of Liaoning Province
Shenyang, Liaoning, 110067
About this study
Official title: A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.
Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
- Conditions
- Human Immunodeficiency Virus Infection
- Being tested
- SHR2150 tablet、efavirenz
- Medical subject headings
- Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHR2150 tablet、efavirenzDrug
SHR2150 tablet single dose, Efavirenz single dose.
| Study group | Role | What they receive |
|---|---|---|
| Treatment group | Experimental | SHR2150+ efavirenz Receives: Drug: SHR2150 tablet、efavirenz |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tmax
Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose
Measured: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Cmax
Maximum observed serum concentration (Cmax) for SHR2150 after Single dose
Measured: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
AUC0-t
Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose
Measured: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
AUC0-inf
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose
Measured: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
T1/2
Time to elimination half-life (T1/2) for for SHR2150 after Single dose
Measured: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Secondary outcomes (1)
Number of subjects with adverse events and the severity of adverse events
Measured: from Day 1 to Day 37 after the first dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2021
- Study start13 Dec 2021
- Primary completion15 Jan 2022 (estimated)
- Study completion22 Jan 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Human Immunodeficiency Virus InfectionStudies of the same condition, open and under way.
- More trials run by Jiangsu HengRui Medicine Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The study is a single-centre, single-arm, open-label and fixed-sequence clinical trial.
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05141422
- Sponsor's protocol ID
- SHR2150-I-105
- Status last verified
- Dec 2021
- First submitted
- 19 Nov 2021
- Last updated
- 20 Dec 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects
- ClinicalTrials.gov ID
- NCT05141422
- Acronym / sponsor ID
- SHR2150-I-105
- Conditions
- Human Immunodeficiency Virus Infection
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 13 Dec 2021 (actual)
- Primary completion
- 15 Jan 2022 (estimated)
- Study completion
- 22 Jan 2022 (estimated)
- First posted
- 2 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.
Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The study is a single-centre, single-arm, open-label and fixed-sequence clinical trial.
| Arm | Type | Receives |
|---|---|---|
| Treatment group | Experimental | Drug: SHR2150 tablet、efavirenzSHR2150+ efavirenz |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
- Healthy subjects aged 18 ~ 45 (including the boundary value), male and female;
- Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2 (m2));
- The physical examination, vital signs, laboratory examination, 12-lead electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no clinical significance;
- The subjects with reproduction ability must agree to take effective contraceptive measures after signing the informed consent form and within 7 months (for female) or 4 months (for male) until the last medication.
Key exclusion criteria (11 listed)
- Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results;
- Those who have undergone surgery within 3 months before the trial, or plan to perform surgery during the study period;
- Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval (QTcF) ≥ 450 ms (for male) or > 460 ms (for female) or < 300 ms;
- Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment;
- Have a history of allergies to drugs, food or other substances;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHR2150 tablet、efavirenzSHR2150 tablet single dose, Efavirenz single dose. | Drug | Treatment group |
Primary outcome
Tmax
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose
Cmax
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Maximum observed serum concentration (Cmax) for SHR2150 after Single dose
AUC0-t
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose
AUC0-inf
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose
T1/2
Time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Time to elimination half-life (T1/2) for for SHR2150 after Single dose
1 secondary outcome
Number of subjects with adverse events and the severity of adverse events
Time frame: from Day 1 to Day 37 after the first dose
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Human Immunodeficiency Virus Infection
Enrolling by invitation
Promoting Aging and Thriving With HIV
HIV (Human Immunodeficiency Virus), Geriatric
RecruitingObservational study
Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide
HIV (Human Immunodeficiency Virus), Pregnancy
Enrolling by invitation
Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy
Pregnant HIV Positive Women
Active, not recruitingPhase 2
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Hepatitis B
RecruitingPhase 4
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
HIV-1-infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing SHR2150 tablet、efavirenz in people with Human Immunodeficiency Virus Infection, run by Jiangsu HengRui Medicine Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tmax (time frame: from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2021.